Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety

Published:2024-01-21 Issue:4 Volume:59 Page:579-580
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sagami Shintaro¹^ORCID,Kobayashi Taku¹^ORCID

Affiliation:

1. Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan

Abstract

LINKED CONTENTThis article is linked to Panaccione et al papers. To view these articles, visit https://doi.org/10.1111/apt.17816 and https://doi.org/10.1111/apt.17853

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17829

Reference9 articles.

1. Improving IBD outcomes in the era of many treatment options

2. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

3. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

4. Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP